KIT and heart failure: This trial aimed to evaluate the feasibility, safety, and efficacy of transendocardial administration of autologous MSCs (target dose: 150 million) and cardiac stem cells (c-kit +) (target dose: 5 million), alone and in combination, in patients with heart failure caused by chronic ischemic cardiomyopathy.